CancerWorld/LinkedIn
May 28, 2025, 08:55
Why Are Patient-Reported Outcomes Still an Afterthought in Clinical Trials? – CancerWorld
CancerWorld shared a post on LinkedIn:
“WHY are patient-reported outcomes (PROs) still an afterthought in Clinical Trials?
For over 15 years, PROs have been hailed as the gold standard for measuring treatment impact on patients’ quality of life.
But in drug development? Still sidelined.
- Fragmented tools
- Conflicting stakeholder priorities
- Lack of early regulatory alignment
- Too time-consuming, or so they say.
In this Cancer World deep-dive, Dr. Manuela Maria Campanelli explores why trials still aren’t built around what matters most to patients, and how that must change.
Essential reading for oncologists, policymakers, regulators, and Patient Advocates shaping the future of Cancer Care.
More posts featuring CancerWorld.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35
May 29, 2025, 13:11